Source - LSE Non-Regulatory
RNS Number : 7551Y
Yourgene Health PLC
17 May 2021
 

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

 

Further testing service agreement for MyHealthChecked plc

 

Yourgene Genomic Services to support MHC's second Boots agreement for Day 2 & Day 8 testing

 for international arrivals to the UK 

 

Manchester, UK - 17 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its partner MyHealthChecked plc (AIM:MHC) ("MyHealthChecked") has signed a second COVID-19 testing services agreement, to support the supply of the MyHealthChecked™ COVID-19 at-home nasal swab kit, PCR laboratory testing service and logistics for day two and day eight ("D2/D8") coronavirus testing for international arrivals, to Boots UK Limited ("Boots"), the health and beauty retailer and pharmacy group.

 

Through the service agreement, a proportion of the MyHealthChecked™ COVID-19 tests will be processed by Yourgene Genomic Services ("YGS") at the Company's Citylabs 1.0 laboratory in Manchester which are well equipped to deal with the anticipated increased demand for D2/D8 testing. In addition, samples processed at MyHealthChecked's own laboratories will use Yourgene's Clarigene® SARS CoV-2 PCR CE-IVD test kit. MyHealthChecked is currently the only at-home testing kit provider within Boots for General Testing and Fit-to-Fly services, as launched on 7 April 2021, and is now accompanied by D2/D8 tests that will be available to purchase online, via www.boots.com across the UK, from 17 May 2021.

 

Lyn Rees, CEO of Yourgene Health and Non-Executive Director of MyHealthChecked, commented: "This further contract with Boots is another significant milestone for MyHealthChecked and Yourgene is pleased to continue supporting their COVID-19 testing service and product supply to their laboratory. With the introduction of the new traffic light system in the UK for global travel, we will see an increased demand for D2/D8 testing, as travel resumes, and this further contract for MyHealthChecked is a testament to the quality of the service provided." 

 

 

Yourgene Health plc

Lyn Rees, Chief Executive Officer

Tel: +44 (0)161 669 8122

investors@yourgene-health.com

Barry Hextall, Chief Financial Officer


Joanne Cross, Director of Marketing


 

N+1 Singer (Joint Corporate Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / Tom Salvesen / George Tzimas




Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Tel: +44 (0)20 7710 7600

Nicholas Moore / Matthew Blawat / Ben Maddison




Walbrook PR Ltd (Media and Investor Relations)

Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / Mob: 07584 391 303 




 

 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

                                                                                                                                                                                         

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAAFMRTMTJBBFB
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.